Epidermolysis Bullosa Pathogenesis and Therapeutic Approaches

Epidermolysis bullosa (EB) comprises a group of inherited genodermatoses characterised by mechanical fragility of the skin and mucous membranes, leading to recurrent blistering, chronic wounds, fibrosis and, in some subtypes, aggressive squamous cell carcinoma. Genetic defects affect structural proteins at the dermal–epidermal junction, most notably collagen VII, laminin-332 and keratin complexes, compromising anchoring fibrils and cytoskeletal integrity. Pathogenic cascades involve inflammation, aberrant wound healing, TGF-β-driven fibrosis and potential malignant transformation. Therapeutic strategies aim to restore protein function or mitigate secondary pathology. Molecular approaches include viral and non-viral gene delivery, genome editing with CRISPR-Cas systems and mRNA therapies; cell-based treatments employ autologous induced pluripotent stem cell-derived grafts or haematopoietic transplantation; protein replacement and small-molecule drugs target extracellular matrix repair and fibrotic pathways. Symptomatic care remains essential, encompassing advanced wound dressings, pain management and nutritional support, while emerging interventions strive to deliver durable, curative outcomes.

Research from Nature Portfolio

Recent studies have established a scalable autologous organotypic cell therapy for dystrophic EB using induced pluripotent stem cell-derived skin composites. By integrating CRISPR-mediated correction of COL7A1 and direct reprogramming into a clinical-grade workflow, researchers generated dermal and epidermal progenitors enriched for holoclone keratinocyte stem cells. Xenografting in murine models demonstrated durable anchoring fibril restoration, lesion healing and a favourable safety profile under cGMP conditions, marking a significant advance towards personalised, definitive treatment.

Separate clinical data from a topical gene therapy trial evaluated a replication-incompetent herpesvirus vector carrying COL7A1 delivered directly to RDEB wounds. In a placebo-controlled phase 1/2 study, treated lesions exhibited de novo collagen VII deposition, anchoring fibril assembly and accelerated wound closure without severe adverse events or vector shedding. These findings validate a non-invasive, repeatable molecular corrective approach that promotes sustained tissue repair.

Epidermolysis Bullosa Pathogenesis and Therapeutic Approaches publication trend

The graph below shows the total number of articles in epidermolysis bullosa pathogenesis and therapeutic approaches across all publications each year (not limited to Nature Index journals).

Technical terms

Anchoring fibrils: Collagen VII-rich structures that secure the epidermis to the dermis.

COL7A1: Gene encoding collagen VII, defects of which underlie dystrophic EB.

CRISPR-Cas9: Genome-editing system enabling precise correction of DNA mutations.

Induced pluripotent stem cell: Somatic cell reprogrammed to a pluripotent state for autologous therapies.

Organotypic skin composite: Bioengineered graft containing epidermal and dermal cell layers mimicking native skin.

Angiotensin II receptor blocker: Small-molecule drug that antagonises TGF-β-mediated fibrosis in EB.

References

1. Challenges and progress related to gene editing in rare skin diseases. Advanced Drug Delivery Reviews (2024).
2. A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa. Nature Communications (2024).
3. Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial. EClinicalMedicine (2024).
4. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nature Medicine (2022).
5. CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. npj Regenerative Medicine (2016).